Evolv Touts Screening Milestone Amid Growth Deceleration and Profitability Risks

What happened

Evolv announced it has screened over four billion people worldwide, surpassing the TSA's daily volume in 2025, a promotional highlight of its market reach. However, the DeepValue report reveals that recent growth, including Q3'25 revenue, relied on non-recurring items like a large customer order and legacy license fees now phasing out. ARR growth is decelerating to around 20% for 2026, down from prior levels, with subscription margins falling due to equipment disposals and field service costs. Legal overhangs from FTC actions and securities lawsuits persist, threatening cash reserves and adding uncertainty to the business model. Despite the operational achievement, Evolv's path to sustainable profitability remains constrained by capital intensity, internal control weaknesses, and slowing normalized growth.

Implication

The screening volume demonstrates operational scale but does not address critical financial weaknesses like declining subscription margins or the phasing out of high-margin license revenue. Growth is slowing as one-time items roll off, making it harder to justify the current market cap amid guided deceleration to low-teens revenue growth in 2026. Ongoing legal settlements could drain the company's $56.2 million liquidity, impairing its ability to fund the capital-intensive leasing model and increasing dilution risk. Without clear evidence of margin recovery and positive free cash flow, the stock's upside is limited, and any disappointment could trigger multiple compression. Current holders should consider trimming near $9.00, while new investors should wait for a cheaper entry below $5.50 or proof of self-funding beyond adjusted metrics.

Thesis delta

This news does not materially shift the investment thesis. The milestone reinforces operational execution but fails to alleviate core concerns over growth normalization, margin pressure, and legal overhangs highlighted in the DeepValue report. Investors should maintain a cautious stance, as the fundamental risks of decelerating ARR, capital intensity, and potential cash outlays remain unchanged.